Lymphomas
Select Clinical Trial
Protocol Number: SWOG 1826 Hodgkin Lymphoma
Protocol Title: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 18 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.
Eligibility: Patient population age 18 years or older with newly diagnosed advanced stage Classical Hodgkin Lymphoma.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: EZH-302
Protocol Title: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma
Eligibility: 18 years or older who have been previously treated with at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy for follicular lymphoma and have documented relapsed, refractory, or progressive disease.
Contact Information: (910) 715-2200